Erschienen in:
01.06.2011 | Letter to the Editor
Circulating Fibroblast Growth Factor-23 Increases Following Intermittent Parathyroid Hormone (1–34) in Postmenopausal Osteoporosis: Association with Biomarker of Bone Formation
verfasst von:
Geeta Hampson
Erschienen in:
Calcified Tissue International
|
Ausgabe 6/2011
Einloggen, um Zugang zu erhalten
Excerpt
We thank Mahon and Casey for their interest in our paper [
1]. We agree with them that our study population is not representative of the usual population treated with bisphosphonates. As described in our article, the patients either were intolerant to or had had an unsatisfactory response to oral bisphosphonates and therefore qualified for treatment with PTH analogue (teriparatide) as set out by the NICE guidance. This would explain the lack of suppression seen at baseline in the bone turnover markers. …